Patients
´
characteristics in mCRPC trials
PREVAIL
(Enzalutamide)
COU-AA-302
(Abiraterone)
TAX 327
(Docetaxel)
ALSYMPCA
(Radium-223)
IMPACT
(Sipuleucel-T)
Patients
characterists
Asymtomatic or
Minimally
Asymtomatic or
Minimally
Most of them
Symtomatic
Symptomatic
Asymtomatic or
Minimally
ECOG
0-1
0-1
0-2 (IK 60%)
0-2
0-2
BPI
≤3
≤3
Any
Symptomatic
≤3
Visceral disease
Allowed
Excluded
Allowed
Excluded
Excluded
OS
35.3
34.7
18.9 m
14.9 m
25.9
